·  History
 Archive
 
 peptide and neuropeptide  WHAT'S NEW
 peptide and neuropeptide  ONLINE CATALOG
 peptide and neuropeptide  CUSTOM SYNTHESIS
 peptide and neuropeptide  ANALYTICAL DATA SHEET (ADS)
 peptide and neuropeptide  SERVICES
 peptide and neuropeptide  TECHNICAL LIBRARY
 peptide and neuropeptide  DOCUMENTS
 peptide and neuropeptide  SITEMAP
 peptide and neuropeptide  JOBS
 peptide and neuropeptide  CONTACT
   BOOKMARK & SHARE
  © Bachem AG
Breaking News Archive    
 
To view our latest information only, go to our portal.



June 17, 2010

Bachem sells stake in Polyphor to Ingro Finanz AG
Bachem today announced that the company on June 16, 2010, has sold its complete stake in Polyphor AG to Ingro Finanz AG. The involved parties have agreed not to disclose the purchase price in the transaction.

peptidePress ReleasepeptidesPressemitteilung


May 19, 2010

12 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


March 22, 2010

16 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


March 19, 2010

Bachem confirms high profitability also in the business year 2009
Bachem today confirms high profitability also in the business year 2009, although North America dampens the positive sales growth in Europe. Despite difficult market conditions, sales of 181.8 million CHF and an EBIT-margin of 28.0% were achieved. Proposed dividend remains at high level of 3.00 CHF.

-

Press ReleasepeptideAnnual ReportpeptidesPressemitteilungneuropeptideGeschäftsbericht


January 13, 2010

14 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


November 18, 2009

16 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


September 24, 2009

mondoBIOTECH and Bachem agree long-term cooperation on the development of peptides to fight rare diseases
mondoBIOTECH and Bachem today announced the conclusion of a long-term cooperation.

-

Press ReleasepeptidePressemitteilung


August 14, 2009

Bachem Group Half-Year Results 2009
Compared with the first half of 2008, overall sales are down 7.6% in CHF. The EBIT margin is at 30.1% and thus remains within the medium term target range of 30% to 35%.

-

Press ReleasepeptideHalf-Year ReportpeptidesPressemitteilungneuropeptideHalbjahresbericht


September 16, 2009

31 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


July 15, 2009

31 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


June 30, 2009

Bachem Receives Abbott’s Supplier Excellence Award
Abbott presented its Supplier Excellence Award to Bachem Americas because of outstanding performance and continuous improvement in supplying materials, equipment and services.

more


May 26, 2009

Stephan Schindler to become new CFO of Bachem Group
Bachem today announced that Stephan Schindler will succeed Michael Hüsler as CFO of the Bachem Group in summer, later this year.

-

Press Release Pressemitteilung


May 14, 2009

18 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


April 23, 2009

Annual General Meeting elects new member of the Board of Directors
Bachem announced today that Dr. Jürgen Brokatzky-Geiger was elected at the Annual General Meeting of Bachem Holding AG of April 22, 2009 as a new member of the Board of Directors.

-

Press Release Pressemitteilung


March 31, 2009

Bachem and Debiopharm sign follow-up contract for long-term supply of Triptorelin Pamoate
Bachem and Debiopharm today announced the conclusion of a follow-up agreement for the long-term supply of Triptorelin Pamoate.

-

Press Release Pressemitteilung


March 18, 2009

42 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


March 13, 2009

Bachem announces financial results for the business year 2008
In the business year 2008, the Bachem Group achieved sales of CHF 195.0 million. Compared with the previous year, this corresponds to a 2.0% sales growth in local currencies.

Press ReleaseAnnual ReportPressemitteilungGeschäftsbericht


January 28, 2009

Bionor Immuno and Bachem sign agreement on supply of active ingredients and finished dosage forms for Bionor Immuno's vaccine development projects
Bachem and Bionor Immuno announced today the conclusion of an agreement for the development and supply of active pharmaceutical ingredients and finished dosage forms for Bionor Immuno's peptide-based vaccine development projects.

-

Press Release Pressemitteilung


January 28, 2009

23 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


January 27, 2009

Bachem today announces the launch of its new online catalog featuring an improved search function and an increased number of structure images.

browse the new online catalog


January 23, 2009

Bachem has been granted a Certificate of Suitability (CEP 2007-157) for Desmopressin Acetate by the European Directorate for the Quality of Medicines (EDQM). Together with the new certificate, Bachem holds now 13 Certificates of Suitability for its active pharmaceutical ingredients (APIs).

to view the full list click here


November 19, 2008

33 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


September 17, 2008

Bachem enlarges Corporate Executive Committee
 Bachem announced today that Dr. Lester Mills will become the fourth member of the company's Corporate Executive Committee on January 1, 2009. Lester Mills will be responsible for global Marketing and Sales.

-

Press Release Pressemitteilung


September 17, 2008

44 new products have been added to the online catalog today.
Check out the complete list of additions.

new products

August 15, 2008

Bachem Group Half-Year Result 2008
Sales of the Bachem Group reached CHF 98.7 million in the first six months of 2008. In local currencies, sales increased slightly by 0.7%.

Press ReleaseHalf-Year ReportPressemitteilungHalbjahresbericht


July 16, 2008

48 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


May 14, 2008

33 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


April 10, 2008

Action Pharma and Bachem cooperate on AP214 - now ready to enter Phase 2 clinical trials
Action Pharma A/S and Bachem today announced their cooperation on AP214, Action Pharma's lead compound, about to enter Phase 2 clinical trials in post-surgical organ failure.

Press ReleasePressemitteilung


March 14, 2008

Record year for Bachem at all levels in 2007
Sales grow to CHF 198.3 Million - up 17.0% in local currencies and 15.5% in CHF respectively.
Operating profit up 29.9%, net income up 37.0%.

Press ReleaseAnnual ReportPressemitteilungGeschäftsbericht


March 12, 2008

22 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


February 4, 2008

Bachem production facilities licensed for the manufacture of APIs for the Japanese market
Bachem announced today that the Japanese Ministry of Health, Labour and Welfare has granted the company a manufacturing license in conformity with the new regulations.

Press ReleasePressemitteilung


January 15, 2008

48 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


September 19, 2007

15 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


August 17, 2007
New record results for Bachem in the first half of 2007
With an increase in sales of 25.4% in CHF or 26.3% in local currencies compared with the first six months of 2006, the Bachem Group posted a new half-year record of CHF 103.0 million in turnover.

Press ReleaseHalf-Year ReportPressemitteilungHalbjahresbericht


August 9, 2007

Bachem Joint Venture Pevion Biotech Secures CHF 35 Million in Series A Financing Round
Bachem today announced that the company has participated in the first substantial private financing round of Pevion Biotech, its joint venture founded in 2002 in partnership with Crucell N.V.

Press ReleasePressemitteilung


July 18, 2007

28 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


July 05, 2007
Bachem has been granted two additional Certificates of Suitability (CEP 2005-245) for Somatostatin and (CEP 2005-250) for Etomidate by the European Directorate for the Quality of Medicines (EDQM). Together with the new certificates, Bachem holds now 11 Certificates of Suitability for its active pharmaceutical ingredients (APIs).

to view the full list click here


June 20, 2007

Bachem renews supply agreement with AstraZeneca
Bachem today announced the renewal of a supply agreement with AstraZeneca. Bachem has supplied AstraZeneca for more than 15 years with goserelin, the active substance of Zoladex, which represents one of AstraZeneca's leading medicines in oncology.

Press ReleasePressemitteilung


June 18, 2007

Bachem acquires Clinalfa® from Merck Biosciences
Bachem announced today that, with effect from July 1, 2007, the company is acquiring the business unit of Merck Biosicences AG, in Läufelfingen, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany, that operates under the brand of Clinalfa®.

Press ReleasePressemitteilung


May 30, 2007

Bachem and Intercell agree long-term supply contract for peptide component of vaccine adjuvant IC31
Bachem and Intercell AG today announced the conclusion of a long-term supply agreement for KLK. In the frame of this agreement, Bachem provides Intercell KLK alternatively from its production sites in Bubendorf, Switzerland, or in Torrance, USA.

Press ReleasePressemitteilung


May 23, 2007

27 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


May 9, 2007

Neuren and Bachem continue close collaboration on Glypromate® - Neuren's lead product now in phase III
Bubendorf/Basel, Switzerland, and Auckland, New Zealand, May 9, 2007 - Bachem and Neuren Pharmaceuticals Limited today announced to continue their close collaboration on Glypromate® , Neuren's lead product currently under development for the prevention of cognitive impairment following major cardiac surgery. Recently the FDA has approved Neuren's investigational drug application (IND) and authorized the company to proceed with a phase III trial. This decision brings the partnership between Bachem and Neuren into a new dimension.

Press ReleasePressemitteilung


March 16, 2007

Bachem reports record results on 2006 sales and profit. The Bachem Group (SWX: BANB) today announced results for the business year 2006. The company achieved a new sales record in 2006 with CHF 171.8 million. Net sales growth was 12.0% in local currencies and 11.8% in CHF compared with 2005. Operating income grew overproportionately by 18.2% to CHF 55.8 million and also net income showed a correspondingly positive development, increasing 18.5% to CHF 46.6 million. Thus, EBIT-margin increased from 30.7% to 32.5% and net income margin from 25.6% to 27.2%.

Press ReleasePressemitteilung


March 14, 2007

18 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


January 17, 2007

28 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


January 11, 2007

Bachem and Ardana Sign Long-term Supply Agreement for Aviptadil Bachem AG and Ardana plc today announced the conclusion of a long-term supply agreement for Aviptadil, an active constituent of Ardana’s Invicorp®. Invicorp®, which also contains the active ingredient phentolamine mesilate, is an intracavernous injectable drug combination for the treatment of male erectile dysfunction and has received marketing approval in Denmark, where it was launched before the end of 2006. Market entry in other European countries is envisaged for 2007.

Press ReleasePressemitteilung


November 22, 2006
Proteinase-activated receptors (PARs) are a class of G-protein-coupled receptors which are involved in various physiological and pathophysiological processes. The new product monograph 'PAR-Activating-Peptides' gives you an overview of Bachem´s PAR-activating-peptides and analogs useful for studying receptor function. Request for your free copy today!
order for free

November 15, 2006

28 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


September 13, 2006

15 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


August 25, 2006

Bachem has been granted a Certificate of Suitability (CEP 2005-022) for Gonadorelin Acetate by the European Directorate for the Quality of Medicines (EDQM). Together with the new certificate, Bachem holds now 9 Certificates of Suitability for its active pharmaceutical ingredients (APIs) such as Calcitonin, Goserelin, Leuprolide, Carbidopa and Propofol.

to view the full list click here


August 18, 2006
Bachem posts sharp rise in profits in the first half of 2006
- Sales growth of 16.3% in CHF and 14.4% in local currencies
- Operating profit and net profit up 40%
- Business in Europe enjoys new impetus
- Sales expectations for the second half of 2006 above the record performance of the previous year

Press ReleaseHalf-Year ReportPressemitteilungHalbjahresbericht


August 11, 2006
Bachem extends its wide range of publications by offering the new monograph
'A Practical Guide for the Custom Peptide User'. Therein we present the many different aspects of peptide production and provide answers to the custom peptide user`s most frequently asked questions. Request for your free copy today!
order for free

July 27, 2006
Bachem Completes Expansion of Peptide Manufacturing Capacities in the US. The Bachem Group (SWX: BANB) announced today that it has opened its new production unit at its US subsidiary Bachem California Inc. in Torrance, California. The expansion offers a forty percent increase in production capacity at the current facility for peptide-based active pharmaceutical ingredients (APIs) to meet increasing market demand in North America. The additional unit, representing an investment of about USD 10 million (CHF 12.5 million), fulfills all FDA requirements for cGMP production.

Press ReleasePressemitteilung


July 19, 2006

32 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


June 30, 2006
Bachem offers an extensive number of product monographs and product datasheets, highlighting the value of Bachem's high quality products. To view our full list of free available brochures, click here. Most recently, the monograph Endothelins as well as the product datasheet Peptide YY (3-36) (human) Acetate have been released.
EndothelinsPeptide YY (3-36) (human) Acetate

May 30, 2006

Bachem announces the release of a completely revised and updated edition of the Immunology Catalog. Our new comprehensive and extended catalog features a number of new additions such as full-color immunohistochemistry tissue sections, a listing of our products indexed by research area as well as Western blots, standard curves, and cross-reactivity tables alongside our products. Request your new 2006 Immunology Catalog today!

order for free

May 17, 2006

18 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


April 7, 2006
Bachem reports record year: highest turnover in the company's history and marked net income growth
- Record sales driven by strong second half and continued dynamic growth of the active ingredients business, as well as demand in the US
- Operating income grows over-proportionally by 13.4% to CHF 47.0 million
- Net income soars by 27.7% to CHF 39.2 million
- Dividend increase from CHF 1.20 to CHF 1.50
- High level of purchase orders promises further growth for 2006

Press ReleaseAnnual ReportPressemitteilungGeschäftsbericht


March 29, 2006
Bachem Group with new production unit for cytotoxic substances. The Bachem Group announced today that, at the end of 2005, its subsidiary Sochinaz SA completed the construction of a new production unit at its site in Vionnaz, Switzerland, for the manufacture of cytotoxic and cytostatic substances. These substances are used as active ingredients for cancer therapy and have to be manufactured according to the strictest safety requirements for both staff and the environment. The investments for the plant, which is licensed for production according to Good Manufacturing Practice (cGMP) principles, amounted to CHF 4 million.

Press ReleasePressemitteilungCommuniqué de presse


March 21, 2006
mondoBIOTECH and Bachem sign collaboration agreement for the development of new projects deriving from the Bachem Peptide Library. mondoBIOTECH AG and Bachem AG today announced a new collaboration agreement for the development of new peptide projects for potential therapeutic use in different medical indication areas. Under the terms of the agreement, Bachem grants mondoBIOTECH exclusive general access to its Peptide Library for screening and selecting suitable compounds for the development of new medications. In return, Bachem has the right to produce any peptides selected as potential drug candidates for development and, if approved as pharmaceuticals, the API of the drug.

Press ReleasePressemitteilung


March 16, 2006
Bachem and Debio conclude long-term supply agreement for triptorelin pamoate. Bachem AG today announced the conclusion of a long-term agreement with Debio, a Swiss drug development company, for the supply of triptorelin pamoate. Unter the terms of this agreement, Bachem will supply Debio with the active substance for its product Decapeptyl® (Trelstar® in the USA). Triptorelin pamoate is a peptidic active pharmaceutical ingredient (API), which is used for treating prostate cancer, endometriosis and premature puberty.

Press ReleasePressemitteilung


March 15, 2006

Bachem offers 19 new products for Alzheimer's research. In total, 49 new items have been added today to our already extensive collection of research products.

new products


March 9, 2006
Swedish Orphan International and Bachem conclude long-term supply agreement for nitisinone. Bachem AG, Bubendorf, Switzerland and Swedish Orphan International AB, Stockholm, Sweden, today announced the conclusion of an agreement for the supply of nitisinone over several years. Under the terms of this agreement, Bachem will supply Swedish Orphan International with the active pharmaceutical ingredient for its product Orfadin.

Press ReleasePressemitteilung


January 27, 2006
Bachem 2005 - Strong second half drives record sales. The Bachem Group (SWX: BANB) recorded its highest sales ever in 2005, totaling CHF 153.7 million. This represents an increase of 3.9% in CHF and 3.4% in local currencies over the previous year. The 2005 success was driven by the positive business trend during the second half of the year, with the fourth quarter proving to be particularly strong. In line with expectations, sales significantly increased during the second half of 2005 by 14.1% in CHF and by 12.1% in local currencies as compared to the corresponding period of 2004. In comparison to the first six months of 2005, sales increased by 17.8% in CHF and 14.1% in local currencies, respectively.

Press ReleasePressemitteilung


January 20, 2006
Bachem offers revised editions of its useful brochures:
- SASRIN - A valuable tool in solid phase peptide chemistry
- The Bachem Practice of SPPS - Tips and tricks
Order your free brochure today.
moreSASRINSPPS

January 11, 2006

71 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


November 24, 2005
Read our article published in Tetrahedron Letters:
Peptide thioester preparation based on an N-S acyl shift reaction mediated by a thiol ligation auxiliary

moredownload


November 08, 2005
Read our article published in Journal of Peptide Science:
The aspartimide problem in Fmoc-based SPPS. Part III.

moredownload


September 14, 2005

33 new products have been added to the online catalog today. peptide yy
Check out the complete list of additions. peptide and biochemicals peptide yy

peptide biochemicals neuropeptide peptide yy neuro peptidenew products

September 08, 2005
Bachem offers a new product monograph for VIP/PACAP
and a product datasheet for Aviptadil.
AviptadilVIP/PACAP

August 16, 2005
Bachem announces half-year results and confirms positive perspective for the second half of 2005
- Improvement of EBIT and net income margins despite slightly weaker sales in local markets
- First half results impacted by continuing dollar weakness
- Purchase orders for the coming 18 months at all time high
- Perspectives confirm expectations for double-digit increase in sales and income for the second half

Press ReleaseHalf-Year ReportPressemitteilungHalbjahresbericht


July 13, 2005

44 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


June 29, 2005
Bachem continues its commitment to peptide chemistry at the University of Basel. As announced today by Bachem Holding AG (SWX: BANB) and the University of Basel, the company is renewing its financial sponsorship of the Bachem Professorship for Peptide Chemistry for a further three years. Accordingly, Bachem will provide a total of CHF 450,000 to the University of Basel up to mid-2008, in order to support the research projects of the current holder of the Chair, Professor Dr. Helma Wennemers, which have been ongoing since 1999.

Press ReleasePressemitteilung


June 20, 2005
Bachem offers a new product monograph for FRET Substrates.
order for free

May 23, 2005
Read our article published in Tetrahedron Letters:
A short practical synthesis of 2'-deoxymugineic acid.

moredownload


May 11, 2005

20 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


April 28, 2005
Basel-Gentilino and Bubendorf, Switzerland, April 28, 2005. The biotech company mondoBIOTECH Holding SA and the peptide manufacturer Bachem (SWX: BANB) today announced a collaboration agreement for the production and supply of the active substance Thymopentin (TP-5). mondoBIOTECH is entering phase I clinical trials in the treatment of severe pulmonary diseases.

Press ReleasePressemitteilung


April 26, 2005
The Bachem Group (SWX: BANB) today announced that Reto Conrad, CFO and member of the Corporate Executive Committee of Bachem Holding AG will leave the company on June 30 this year. He will be succeeded by Michael Hüsler, currently Head Corporate Controlling of Straumann Holding AG.

Press ReleasePressemitteilung


April 25, 2005
Read our article published in Molecular Pharmology:
Targeting Effector Memory T Cells with a Selective Peptide Inhibitor of Kv1.3 Channels for Therapy of Autoimmune Diseases.

moredownload


April 21, 2005
Read our article published in the Journal of Biological Chemistry:
Bass Hepcidin Synthesis, Solution Structure, Antimicrobial Activities and Synergism, and in Vivo Hepatic Response to Bacterial Infections.

moredownload


April 8, 2005
Bachem 2004 results with positive outlook for 2005
- Sales increase in local currencies driven by solid growth of peptide generics
- Operating and net income affected by continued US dollar weakness and margin pressure in non-peptide generics business
- Active ingredients business sees new growth potential with imminent market introduction of new product from Amylin Pharmaceuticals and various other projects in advanced development stage

Press ReleaseAnnual ReportPressemitteilungGeschäftsbericht


April 06, 2005
Bachem's new technical note Solubilization of Peptides is now available.
The solubility of a peptide is primarily dependent on the physical properties of its amino acids. Amino acids can be classified as acidic, basic, polar uncharged, or nonpolar hydrophobic. Peptides with a high content of nonpolar hydrophobic amino acids or polar uncharged amino acids are preferentially solubilized in organic solvents whereas overall acidic peptides can normally be reconstituted in basic solvents and overall basic peptides in acidic solvents.

moredownload


April 04, 2005
Bachem offers a new product datasheet for Fertirelin Acetate.
Fertirelin acetate is a synthetic nonapeptide analog of the naturally occurring gonadotropin-releasing hormone (GnRH), also known as luteinizing hormone-releasing hormone (LHRH). As natural GnRH, fertirelin acetate induces the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary gland which in turn results in an initial increase of testosterone and estradiol synthesis.

moreorder for free


March 31, 2005
Bachem extends its technical notes by the following topic:
Conversion of a DCHA salt to the free acid.
Bachem offers a number of N-protected amino acids as DCHA (dicyclohexylammonium) salts. The production of such salts is preferred if the free amino acid is not available in a crystalline form or if the free acid is unstable. In addition, in some cases DCHA salts of derivatives can be purified in a straight-forward process. However, before starting peptide synthesis, the amino acids have first to be liberated from their DCHA salts.

moredownload


March 29, 2005

Bachem offers Thymosin b4 (human, bovine, horse, rat) which might be of therapeutic value in the setting of acute myocardial damage.
Nature 432, 466-472 (2004).
This product is listed in our catalog as H-2608 and is available as cGMP grade also.

more

March 16, 2005

20 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


February 16, 2005
Bachem offers a new product monograph for Neuropeptide Y. Neuropeptide Y exhibits a large number of physiological activities in the central and peripheral nervous system. There is evidence that neuropeptide Y is implicated in the pathophysiology of a number of diseases such as feeding disorders and metabolic diseases as well as anxiety, seizures, intestinal dysfunction, cardiovascular, and respiratory diseases. Its various effects make neuropeptide Y an attractive target for the potential treatment of several of these diseases.
order for free

February 07, 2005
Read our article published in Current Medicinal Chemistry:
Potassium Channel Blockade by the Sea Anemone Toxin ShK for the Treatment of Multiple Sclerosis and Other Autoimmune Diseases.

moredownload


January 21, 2005
Full Year Sales 2004: Active pharmaecutical ingredients drive growth. Generics sales boosting by 22.5% in local currencies. The Bachem Group (SWX: BANB) today announced its 2004 sales results. In local markets, the company achieved sales growth of 4.7%. This is at the upper limit of the guidance communicated previously. Because ot the significant negative currency impact, due to the weakening of the US dollar by 7.6% as compared to 2003, sales in Swiss francs only slightly increased from CHF 144.6 million to CHF 147.4 million (+1.9%), despite the strengthening of the Euro and British pound vis-à-vis the Swiss franc.

Press ReleasePressemitteilung


January 19, 2005

26 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


January 17, 2005

In addition to the well accepted Periodic Chart of Amino Acids,
Bachem now extends its educational tools by a
Periodic Chart of Unusual a-Amino Acids.
Order your free poster now.

moreprevieworder for free


January 06, 2005
Bachem offers a new product monograph on Secretase Inhibitors and Substrates. The deposition of amyloid b-peptide (Ab) in the brain represents a neuropathological feature of Alzheimer's disease. Ab is cleaved from its precursor protein (APP) by processing at the amino- and carboxy-termini by enzymes known as b- and g-secretases, respectively. Inhibition of amyloid peptide production by inhibitors of b- and g-secretases has been suggested as the most specific therapeutic approach.
order for free

November 17, 2004

53 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


November 12, 2004
Bachem extends its technical notes:
Chromophors/Fluorophors: Spectral Properties and Characteristics.
The advantage of chromogenic and fluorogenic substrates is the facile spectrometrical detection and analysis of the reaction products. This guide contains some useful information about the various kinds of substrates, offered by Bachem.

moredownload


November 05, 2004
Bachem offers a new product monograph for Melanoma Peptides
The number of people who develop melanoma has more than doubled within the past 10 - 15 years. Presently, the incidence of melanoma rises 5 % per annum worldwide. Thus, melanoma represents the cancer that is rising faster than any other solid tumor cancer.
order for free

October 14, 2004
Read our article published in Recent Research Developments in Organic Chemistry: Asymmetric synthesis of (R)- and (S)-a-methylcysteine.

moredownload


September 15, 2004

14 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


September 14, 2004
Bachem AG is pleased to announce the successful completion of a 4-day US-FDA inspection of its Bubendorf (Switzerland) manufacturing site. After previous FDA inspections and approvals in the years 1997 and 2001, the September 2004 inspection confirms the high GMP compliance of Bachem's Bubendorf site.


September 01, 2004
Bachem extends its publications by the following new product monographs:
- Orthogonality of Protecting Groups in Peptide Synthesis by Fmoc Strategy
- N-Methylated Amino Acids
Please order the desired product monographs for free.
OrthogonalityN-Methylated Amino Acids

August 25, 2004
Bachem offers a new product monograph for Diabetes Peptides.
According to the International Diabetes Federation, nearly 200 million people around the world suffer from diabetes. Diabetes mellitus can lead to blindness, kidney failure, and nerve damage. It is also an important factor in accelerating the hardening and narrowing of the arteries, leading to strokes, coronary heart diseases, and other blood vessel diseases. Many pancreatic and gastrointestinal peptide hormones are involved in the control of blood glucose.
order for free

August 17, 2004
Bachem half-year sales 2004 exceed CHF 75 million. In the first half of 2004, the Bachem Group (SWX: BANB) recorded sales growth of 8.0% in local currencies. Business dynamics in the USA and in peptide generics worldwide were primary contributors to this development. The appreciation of the Euro against the Swiss franc could not compensate for a further weakening of the USD by 6.3%, therefore sales increase in CHF was at 6.1%, resulting in a consolidated turnover of CHF 75.5 million as compared to CHF 71.2 million in the corresponding period in 2003.

Pressetext HalbjahresberichtPress ReleaseHalf-yearly Report


July 28, 2004
mondoBIOTECH Holding SA and Bachem AG today announced a collaboration agreement for production and supply of mondoBIOTECH's lead compound Aviptadil. mondoBIOTECH is entering phase II clinical trial to treat pulmonary arterial hypertension and plans to bring Aviptadil to the market in 2007.

Press ReleasePressemitteilung


July 20, 2004
Read our article published recently in the Journal of Immunology:
K+ Channel Expression during B Cell Differentiation:
Implications for Immunomodulation and Autoimmunity.

moredownload


July 07, 2004

28 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


July 02, 2004
Read our article published recently in the Journal of Organic Chemistry:
Efficient Asymmetric Synthesis of (S)- and (R)-N-Fmoc-S-Trityl-a-methylcysteine Using Camphorsultam as a Chiral Auxiliary.

moredownload


June 18, 2004

Pevion Biotech announces positive results in clinical phase I trial for its malaria vaccine. Pevion Biotech, a joint venture of Berna Biotech AG and Bachem AG, reported today that it has met the clinical endpoints of its phase I trial for two components of the PeviPROTM based synthetic malaria vaccine PEV3A. Phase I, which represents the first stage of human testing for a potential vaccine, started in November 2003 and was designed to evaluate safety, tolerability and immunogenicity of the vaccine candidate in healthy volunteers.

PressemitteilungPress Release


May 13, 2004

24 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


May 05, 2004
Bachem extends its publications by the following three new product data sheets:
- Buserelin Acetate Ph. Eur.
- Histrelin Acetate
- Protirelin Ph. Eur.
Please order the desired product data sheets for free.
BuserelinHistrelinProtirelin

May 04, 2004
Read our article published recently in Trends in Pharmacological Sciences:
K+ channels as targets for specific immunomodulation.

moredownload


April 20, 2004
The Bachem Group (SWX: BANB) today announced results for the business year 2003. Total sales in local markets grew by 1.8%. In face of the strong negative currency impact of the weakened US dollar, sales in Swiss francs diminished by 3.5%. Nevertheless, it was possible to increase EBIT by 0.3% from CHF 48.3 million to CHF 48.4 million, which resulted in an improvement of EBIT margin from 32.2% to 33.5%. Net profit increased by 11.4%, from CHF 33.5 million to CHF 37.3 million.

Press ReleaseAnnual ReportPressemitteilungGeschäftsbericht


April 16, 2004
Read our article published recently in Bioorganic & Medicinal Chemistry Letters:
Rational design and synthesis of selective BACE-1 inhibitors.

moredownload


March 18, 2004
Jerini AG and Bachem AG today announced a collaboration agreement for production and supply of Jerini's lead compound Icatibant. At present, Icatibant is tested in several clinical trials to treat refractory ascites in liver cirrhosis as well as hereditary angioedema. By 2006 Jerini plan to bring Icatibant to market. Under the terms of the agreement, Bachem will supply Jerini with cGMP-produced Icatibant for clinical trials. Bachem will assume the entire process validation including necessary documentation for the registration process. First approval for Icatibant in the indication angioedema is targeted for 2006.

Press ReleasePressemitteilung


March 17, 2004

21 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


March 17, 2003
Bachem offers a new product monograph for Calcitonin Gene-Related Peptide. CGRP is a 37 amino acid peptide which belongs to a family of related peptides including calcitonin, amylin, and adrenomedullin. It exists in two isoforms a-CGRP (or CGRP I) and b-CGRP (or CGRP II) which are very similar in their biological activities and are encoded by different genes.
order for free

January 23, 2004
Full Year Sales 2003: Bachem reports continued sales growth for its active pharmaceutical ingredients business. The Bachem Group today published its 2003 sales results. In local markets the company achieved sales growth of 1.9%. The significant negative currency impact due to the weakened US dollar - by 14% as compared to 2002 - together with diminished demand for research chemicals resulted in a 3.4% decrease of total sales in Swiss francs from CHF 149.9 million to CHF 144.8 million.

Press ReleasePressemitteilung


January 22, 2004

Now available: The Bachem Catalogs 2004.
In additon to the main catalog, Bachem also offers the special Immunochemicals Catalog and the Building Blocks Catalog, a comprehensive list of products for peptide synthesis. Order the Bachem catalogs 2004 for free.

order for free


January 12, 2004

33 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


January 06, 2004
Read our article published recently in Letters in Peptide Science:
Addition of o-aminobenzoic acid during Fmoc solid phase synthesis of a fluorogenic substrate containing 3-nitrotyrosine.

moredownload


December 23, 2003
Bachem has been granted a Certificate of Suitability (CEP 2001-454) for Leuprolide Acetate by the European Directorate for the Quality of Medicines (EDQM). Please order the concerning product datasheet of Leuprolide Acetate Ph. Eur.

order for free


December 23, 2003
Read our article published recently in Chimica Oggi:
A very bright future for cGMP-manufacturing of peptides.

moredownload


December 15, 2003
Wimbledon title-holder and tennis world champion Roger Federer was presented the Canton Basel-Landschaft Sport Award in the worthy celebratory settings of the Bachem AG, Bubendorf, auditorium.

view detail


December 15, 2003
Bachem offers an Inverse Agonist of Constitutive Ghrelin Receptor Signalling, described recently by B.Holst et al. in Mol. Endocrinol. 17(11), 2201-2210 (2003).
This product is listed in our catalog as H-6935.
more

December 15, 2003
Bachem offers a new overview of the versatile applications of SASRIN, the Super Acid-Sensitive Resin. Download this valuable tool with many useful procedures for solid phase peptide chemistry.

download


December 12, 2003
Bachem has been granted a Certificate of Suitability (CEP 2003-037) for Goserelin Acetate by the European Directorate for the Quality of Medicines (EDQM). Please order the concerning product datasheet of Goserelin Acetate Ph. Eur.

order for free


November 12, 2003

29 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


October 30, 2003
Bachem offers a new product monograph for Peptide YY.
Peptide YY (PYY) is a gut hormone which was first isolated in 1980 by Takemoto and coworkers from porcine intestine. It belongs to a structurally and functionally related family of peptides, which also includes neuropeptide Y (NPY) and pancreatic polypeptide (PP).

order for free


October 21, 2003
Bachem offers a new product datasheet for Gonadorelin Acetate Ph. Eur.
Gonadorelin is a hypothalamic decapeptide which induces the release of luteinizing hormone and follicle-stimulating hormone from the anterior pituitary.

moreorder for free


October 21, 2003
Bachem offers a new product datasheet for Octreotide Acetate.
Octreotide acetate is a synthetic octapeptide analog of the naturally occurring hormone somatostatin, with similar physiological actions, but longer biological half-life and higher potency.

moreorder for free


September 1, 2003

Additional non peptidic APIs are now available:
- Xipamide
- Zonisamide
These APIs are produced by Sochinaz, a Bachem group company.
Please click here to view the full list of our generic APIs.

XipamideZonisamide

August 29, 2003

36 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


August 25, 2003
Bachem offers a new product monograph for Ghrelins.
Ghrelin is an endogenous peptide with an essential n-octanoyl modification on the hydroxy group of Ser3 and displays strong growth hormone-releasing activity mediated by the growth hormone secretagogue receptor (GHS-R). It also participates in the regulation of energy homeostasis, increases food intake, and decreases energy expenditure by lowering the catabolism of fat.

order for free


August 22, 2003
Half-yearly Results 2003: Bachem Group increases half-year net income with stable sales in local markets. The EBIT margin held up well at 32.1 percent (first half-year 2002: 31.9 Percent). At CHF 23.5 million, income before taxes was up 6.3 percent on the same period last year (first half-year 2002: CHF 22.1 million) thanks to the sharply improved net financial result.

Pressetext HalbjahresberichtPress ReleaseHalf-yearly Report


August 18, 2003
Read our scientific article, published recently in Journal of Peptide Science:
The Aspartimide Problem in Fmoc-based SPPS. Part II

moredownload


July 3, 2003
Bachem offers glucagon-like peptide GLP-1 (1-37) (human, bovine, guinea pig, mouse, rat) the function of which has recently been clarified by A. Suzuki et al. in Proc. Natl. Acad. Sci. USA 100, 5034 (2003).
This product is listed in our catalog as H-5552 .
more

June 27, 2003
Read our scientific article, accepted for publication by the Journal of Biological Chemistry:
"The caspase-like sites of proteasomes: substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites"

moredownload


June 6, 2003
Read our scientific article, published recently in the Journal of Clinical Investigation:
"The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS"

moredownload


June 3, 2003
Bachem offers a new Product Data Sheet for Xylazine Hydrochloride Ph.Eur.
order for free

April 11, 2003
Bachem offers a new product monograph for Luteinizing Hormone-Releasing Hormone (LHRH).

order for free


April 24, 2003
Results 2002: Bachem maintains above-average profitability despite difficult economic conditions. EBIT margin at 32.2% despite weakness of US dollar; payment of CHF 1.00 per share as combination of dividend and reduction of nominal value proposed; Prof. Dr. Hans Hengartner suggested as new member of the Board.
PressemitteilungGeschäftsberichtPress ReleaseAnnual Report

May 6, 2003

17 new products have been added to the online catalog today.
Check out our 10 new immunochemicals and 7 new peptides.

new products


March 31, 2003
Bachem offers a new product monograph for Cysteine and its Derivatives in Peptide Synthesis.

order for free


March 28, 2003
Read our scientific article, published recently in Tetrahedron Letters:
"An efficient asymmetric synthesis of Fmoc-L-cyclopentylglycine via diastereoselective alkylation of glycine enolate equivalent"

moredownload


March 17, 2003
Bachem offers a new Product Data Sheet for Sincalide.
order for free

March 7, 2003
Bachem extends its publications by the following new product monographs:
- Amyloid Peptides
- Prion Peptides
Please order the desired product monographs for free.
Amyloid PeptidesPrion Peptides

February 6, 2003

Now available: The Bachem Catalogs 2003.
In additon to the main catalog and the third edition of the special Immunochemicals Catalog, Bachem has also launched a new special Building Blocks Catalog, a comprehensive list of products for peptide synthesis.
Order the Bachem catalogs 2003 for free.

order for free


February 4, 2003
Read our publication, submitted to the Journal of Biological Chemistry:
"A novel fluorescent toxin to detect and investigate Kv1.3 channel upregulation in chronically activated T lymphocytes".

moredownload


January 23, 2003
Bachem grows sales by 9.7% in local currencies. The Bachem Group increased sales by 5.9% (in Swiss Francs) in 2002, from CHF 141.4 million to CHF 149.8 million, despite difficult market conditions. The negative currency effect is primarily attributable to the weakness of the US dollar in 2002 as compared to the previous year.
PressemitteilungPress Release

January 22, 2003
Bachem and AstraZeneca extend supply agreement under which Bachem will continue to supply AstraZeneca with Goserelin, the active pharmaceutical ingredient of Zoladex, one of the leading compounds of AstraZeneca in oncology.
PressemitteilungPress Release

January 20, 2003
Bachem professorship for peptide chemistry extended. As part of its engagement in the field of biopharmaceutical research, Bachem will continue its sponsorship of an assistant professor at Basel University, Switzerland. First established in 1999, the Bachem professorship for peptide chemistry is now funded through mid 2005 with a further contribution of CHF 375,000.
PressemitteilungPress Release

January 9, 2003
Bachem extends its publications by the following four new product data sheets:
- Deslorelin Acetate
- Goserelin Acetate Ph.Eur.
- pTH (1-34) (human) Acetate
- Thymosin a1 Acetate
Please order the desired product data sheets for free.
DeslorelinGoserelin pTH (1-34)Thymosin a1

November 19, 2002
Bachem offers the gut hormone Peptide YY (3-36) (human) (PYY (3-36) (human)), that has recently gained great public interest after being mentioned by R.L. Batterham et al. in Nature 418, 650 (2002).
This product is listed in our catalog as H-8585.
more

November 4, 2002
Since the bulletin 2002 was released in August, we added 27 new products to our online catalog.

new products


October 25, 2002
Read our publication, released recently in Biochemistry:
"Mutating a Critical Lysine in ShK Toxin Alters Its Binding Configuration in the Pore-Vestibule Region of the Voltage-Gated Potassium Channel, Kv1.3"

moredownload


September 30, 2002
Bachem offers a new product monograph for Generic Active Pharmaceutical Ingredients (APIs).
moreorder for free

September 27, 2002
Bachem offers a new product data sheet for Triptorelin Acetate.
order for free

August 23, 2002
Bachem shows firm growth in difficult environment and improves operating performance in all markets and business segments. In the first half of 2002, the Bachem Group increased its sales by 16.3% to CHF 76.2 million, compared with CHF 65.5 million in the same period last year. In local currencies, the growth amounted to 18.6%. EBIT rose by 12.4%, from CHF 21.7 million to CHF 24.4 million.
PressetextHalbjahresberichtpress releasehalf-yearly report

August 12, 2002
Since catalog 2002 was released in January, we have added more than 180 new products. Download the entire product file.

download


July 29, 2002
From August 1, 2002, Dr. Jacques-Alain Cotting assumes the full responsibilities as COO of Sochinaz SA. He is following Mr. Christian Borgeaud who takes his retirement after nearly thirty years of service to the company.
www.sochinaz.ch

July 24, 2002
Bachem offers a new product monograph for Matrix Metalloproteinase (MMP).
order for free

July 10, 2002
Bachem extends its publications by the following three new product data sheets:
- Desmopressin Acetate Ph.Eur.
- Glucagon (1-29) (human, bovine, porcine)
- Somatostatin Ph.Eur.
Please order the desired product data sheets for free.
DesmopressinGlucagon Somatostatin

May 16, 2002
Bachem offers new amyloid b-protein products for Alzheimer's disease research.
new products

April 30, 2002
Bachem offers a product-monograph for caspase inhibitors and substrates.
order for free

April 23, 2002
Bachem AG today announced business results for 2001. Sales were up 26.9% in Swiss Francs and 27.3% in local currencies, achieving a new record of CHF 141.4 million. EBITDA (earnings before interest, tax, depreciation and amortization) grew by 13.1% from CHF 55.2 million to CHF 62.4 million, representing 44.2% of sales. EBIT (earnings before interest and tax) increased by 7.4% from CHF 45.7 million to CHF 49.1 million.
press releaseannual report

April 17, 2002
In addition to the peptides Ghrelin (human) and Ghrelin (rat), Bachem offers new immunological products for Ghrelins.
new products

April 02, 2002
Bachem has been granted a Certificate of Suitability (CEP 2000-180) for Calcitonin (salmon) by the European Directorate for the Quality of Medicines (EDQM). Please order the concerning product datasheet of Calcitonin (salmon) Ph.Eur. 2002 for free.
order for free

March 01, 2002
We are proud to offer a newly released product datasheet of Leuprolide Acetate Ph.Eur. which can be ordered for free.
order for free

 Back to
 Archive